Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Predicting outcomes in CNS lymphoma with ctDNA

Jane N. Winter, Andres J. M. Ferreri

Blood (2024) 143 (6): 478–480.

https://doi.org/10.1182/blood.2023023008

Published: 2024

Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Blood (2022) 140 (Supplement 1): 1459–1463.

https://doi.org/10.1182/blood-2022-158024

Published: 2022

Journal Articles

Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 3603–3605.

https://doi.org/10.1182/blood-2022-166535

Published: 2022

Journal Articles

Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy

Blood (2022) 140 (Supplement 1): 6504–6506.

https://doi.org/10.1182/blood-2022-166486

Published: 2022

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Giuseppe Rossi, Henry Miles Prince, Constantine S. Tam, Matthew Ku, Catherine Thieblemont, Leslie L. Popplewell, Martin Wermke, Corinne Haioun, Nicole Wong Doo, Andreas Viardot, Andrés J M Ferreri, Silvia Ferrari, Hansen L. Wong, Priti Kadu, Gerhard Zugmaier, Yi Zeng, Alessandro Rambaldi

Blood (2021) 138 (Supplement 1): 2436.

https://doi.org/10.1182/blood-2021-152822

Published: 2021

Journal Articles

Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms

Blood (2021) 138 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2021-148841

Published: 2021

Journal Articles

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Blood (2021) 138 (Supplement 1): 1417.

https://doi.org/10.1182/blood-2021-147822

Published: 2021

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Blood (2019) 134 (3): 252–262.

https://doi.org/10.1182/blood.2019000633

Published: 2019

Includes: Supplemental data

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Swami P. Iyer, MD, Auris Huen, MD, Andres J M Ferreri, MD, Bradley M. Haverkos, MD MPH, MS, Jasmine M. Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Richard Delarue, MD, Kasi V Routhu, PhD, Prajak Barde, MD, Ajit M Nair, PhD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2018-99-112757

Published: 2018

Journal Articles

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol

Blood (2018) 132 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2018-99-115346

Published: 2018

Journal Articles

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma

Luca Ceriani, Lisa Milan, Maurizio Martelli, Andrés J. M. Ferreri, Luciano Cascione, Pier Luigi Zinzani, Alice Di Rocco, Annarita Conconi, Anastasios Stathis, Franco Cavalli, Monica Bellei, Kelly Cozens, Elena Porro, Luca Giovanella, Peter W. Johnson, Emanuele Zucca

Blood (2018) 132 (2): 179–186.

https://doi.org/10.1182/blood-2018-01-826958

Published: 2018

Includes: Supplemental data

Journal Articles

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Elisabeth Schorb, MD, Chris P Fox, Benjamin Kasenda, MDPhD, Teresa Calimeri, MDPhD, Kim Linton, MBChB PhD, Jeffery Smith, MBChB BMedSci MRCP FRCPath, Slavisa Ninkovic, MBBS FRACP FRCPA, Deborah Yallop, MBBS FRCP FRCPath PhD, Hans-Guido Holl, MD, Alberto Fabbri, MD, Thomas E C Cummin, MRCP MBBCh BSc, Gerald Illerhaus, MD, Kate Cwynarski, PhDMD, Andrés J M Ferreri, MD

Blood (2017) 130 (Supplement 1): 376.

https://doi.org/10.1182/blood.V130.Suppl_1.376.376

Published: 2017

Journal Articles

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Blood (2017) 130 (Supplement 1): 4062.

https://doi.org/10.1182/blood.V130.Suppl_1.4062.4062

Published: 2017

Journal Articles

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project

Andrei Shustov, MD, Maria Elena Cabrera, Monica Bellei, MSc, PhD, Young Hyeh Ko, MD, Martina Manni, PhD, Steven M. Horwitz, MD, Carmino Antonio De Souza, MD PhD, John A. Radford, MD, Sabela Bobillo Varela, Maria Virginia Prates, MD, Andrés J M Ferreri, MD, Carlos Chiattone, MD, Michele Spina, MD, Julie M. Vose, MDMBA, Annalisa Chiappella, MD, Daniele Laszlo, MD, Dario Marino, MDPhD, Caterina Stelitano, Massimo Federico, MD

Blood (2017) 130 (Supplement 1): 4071.

https://doi.org/10.1182/blood.V130.Suppl_1.4071.4071

Published: 2017

Journal Articles

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

Blood (2017) 130 (Supplement 1): 4072.

https://doi.org/10.1182/blood.V130.Suppl_1.4072.4072

Published: 2017

Journal Articles

Safety and Activity of a Dose-Dense Short-Term Chemoimmunotherapy in HIV-Positive Patients with Burkitt Lymphoma (HIV-BL pts): Final Results of the Carmen Phase II Trial

Andrés J M Ferreri, MD, Michele Spina, Chiara Cattaneo, MD, Luisa Verga, MD, Bernardino Allione, Daris Ferrari, Luigi Rigacci, Luca Fumagalli, MD, Giovanni Donadoni, MD, Arben Lleshi, MD, Marianna Sassone, MD, Giuseppe Rossi, MD, Alessandro Re, MD

Blood (2017) 130 (Supplement 1): 2828.

https://doi.org/10.1182/blood.V130.Suppl_1.2828.2828

Published: 2017

Journal Articles

Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial

Blood (2017) 130 (Supplement 1): 1511.

https://doi.org/10.1182/blood.V130.Suppl_1.1511.1511

Published: 2017

NARROW

Predicting outcomes in CNS lymphoma with ctDNA

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi

Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)

Determining Clinical Course of Diffuse Large B-Cell Lymphoma Using Targeted Transcriptome and Machine Learning Algorithms

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma

Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project

Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project

Safety and Activity of a Dose-Dense Short-Term Chemoimmunotherapy in HIV-Positive Patients with Burkitt Lymphoma (HIV-BL pts): Final Results of the Carmen Phase II Trial

Early Reduction of Serum TARC Levels Predicts Prognosis of Patients Treated with a PET-Adapted Strategy for Advanced Stage Hodgkin Lymphoma (HL) in the GITIL/FIL HD0607 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only